Department of Endoscopy, Barretos Cancer Hospital, Barretos, Brazil.
Department of Prevention, Barretos Cancer Hospital, Barretos, Brazil.
Cancer Prev Res (Phila). 2021 Feb;14(2):241-252. doi: 10.1158/1940-6207.CAPR-20-0179. Epub 2020 Sep 30.
Colorectal cancer is the second most common cancer in Brazil. Yet, a nationally organized colorectal screening program is not implemented. Barretos Cancer Hospital (BCH) is one of the largest Brazilian institution that cares for underserved patients. BCH developed a fecal immunochemical test (FIT)-based organized colorectal cancer screening program to improve colorectal cancer outcomes.This study aims to present the quality/performance measures of the first 2 years of the FIT-based colorectal cancer screening program and its impact on the colorectal cancer disease stage. Between 2015 and 2017, a total of 6,737 individuals attending the Outpatient Department of Prevention or the Mobile Unit of BCH, which visits 18 cities of Barretos county, ages 50 to 65 years, were personally invited by a health agent/nurse practitioner. Exclusion criteria were personal history of colorectal cancer, adenomatous polyps, inflammatory bowel disease, and colonoscopy, or flexible sigmoidoscopy performed in the past 5 years. European Union (EU) guidelines for colorectal cancer screening programs were evaluated. Overall, 92.8% returned the FIT, with an inadequate examination rate of 1.5%. Among the 6,253 adequately tested, 12.5% had a positive result. The colonoscopy compliance and completion rates were 84.6 and 98.2%, respectively. The PPVs were 60.0%, 16.5%, and 5.6% for adenoma, advanced adenoma, and cancer, respectively. Stage distribution of screen-detected cancers shows earlier stages than clinically diagnosed colorectal cancer cancers reported at BCH and Brazilian cancer registries. Our colorectal cancer screening program achieved desirable quality metrics, aligned with the EU guidelines. The observed shift toward earlier colorectal cancer stages suggests an exciting opportunity to improve colorectal cancer-related cancers in Brazil.
结直肠癌是巴西第二大常见癌症。然而,巴西尚未建立全国性的结直肠筛查计划。巴雷托斯癌症医院(BCH)是巴西最大的医疗机构之一,致力于为服务不足的患者提供服务。BCH 开发了一种基于粪便免疫化学检测(FIT)的结直肠癌症筛查计划,以改善结直肠癌的预后。本研究旨在介绍基于 FIT 的结直肠癌症筛查计划实施的前 2 年的质量/绩效指标及其对结直肠癌疾病分期的影响。2015 年至 2017 年期间,共有 6737 名来自 BCH 门诊预防部门或流动单位的患者参加了这项研究,这些患者年龄在 50 至 65 岁之间,来自巴雷托斯县的 18 个城市,他们由一名健康代理人/执业护士亲自邀请。排除标准包括个人结直肠癌病史、腺瘤性息肉、炎症性肠病以及过去 5 年内进行的结肠镜检查或乙状结肠镜检查。评估了欧盟(EU)结直肠癌筛查计划的指南。总体而言,92.8%的人返回了 FIT,检查不充分的比例为 1.5%。在 6253 名接受充分检测的患者中,有 12.5%的人结果呈阳性。结肠镜检查的依从率和完成率分别为 84.6%和 98.2%。腺瘤、高级别腺瘤和癌症的 PPV 分别为 60.0%、16.5%和 5.6%。筛查发现的癌症的分期分布显示出比 BCH 和巴西癌症登记处报告的临床诊断结直肠癌更早的阶段。我们的结直肠癌症筛查计划达到了理想的质量指标,符合欧盟指南。观察到的结直肠癌分期向更早阶段的转变表明,巴西有机会改善结直肠癌相关癌症。